Cargando…

Direct oral anticoagulants: a new therapy against Alzheimer’s disease?

Detalles Bibliográficos
Autor principal:	Grossmann, Klaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323692/ https://www.ncbi.nlm.nih.gov/pubmed/33433480 http://dx.doi.org/10.4103/1673-5374.303029

Ejemplares similares

Direct Oral Anticoagulants (DOACs) for Therapeutic Targeting of Thrombin, a Key Mediator of Cerebrovascular and Neuronal Dysfunction in Alzheimer’s Disease
por: Grossmann, Klaus
Publicado: (2022)

Anticoagulants for Treatment of Alzheimer’s Disease
por: Grossmann, Klaus
Publicado: (2020)

Direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism
por: Yhim, Ho-Young, et al.
Publicado: (2014)

Hyperbaric oxygen therapy as a new treatment approach for Alzheimer’s disease
por: Shapira, Ronit, et al.
Publicado: (2018)

New horizons in anticoagulation: Direct oral anticoagulants and their implications in oral surgery
por: Serrano-Sánchez, Víctor, et al.
Publicado: (2017)

Use of New Oral Anticoagulants / Direct Oral Anticoagulants in Malignant Patients
por: Khan, Yusra, et al.
Publicado: (2020)

Embolic stroke of undetermined source: identification of patient subgroups for oral anticoagulation treatment
por: Greeve, Isabell, et al.
Publicado: (2021)

Advancing combination therapy for Alzheimer's disease
por: Salloway, Stephen P., et al.
Publicado: (2020)

New Approaches to Treating Alzheimer’s Disease
por: Zheng, Hailin, et al.
Publicado: (2015)

Aquaporin 5 in Alzheimer’s disease: a link between oral and brain pathology?
por: Municio, Cristina, et al.
Publicado: (2022)

Tetrahydrohyperforin: a neuroprotective modified natural compound against Alzheimer's disease
por: Montecinos-Oliva, Carla, et al.
Publicado: (2015)

Pharmacogenetics in the Management of Coumarin Anticoagulant Therapy: The Way Forward or an Expensive Diversion?
por: Greaves, Mike
Publicado: (2005)

Targeting immunometabolic pathways for combination therapy in Alzheimer's disease
por: Erichsen, Jennifer, et al.
Publicado: (2023)

Lingo-1: a novel target in therapy for Alzheimer's disease?
por: Fernandez-Enright, Francesca, et al.
Publicado: (2016)

Direct Oral Anticoagulants or Standard Anticoagulant Therapy in Fragile Patients with Venous Thromboembolism
por: López-Núñez, Juan J., et al.
Publicado: (2019)

New approaches for prevention and treatment of Alzheimer's disease: a fascinating challenge
por: Piemontese, Luca
Publicado: (2017)

Myelin lipid deficiency: a new key driver of Alzheimer’s disease
por: Qiu, Shulan, et al.
Publicado: (2022)

New Direct Oral Anticoagulants (DOAC) and Their Use Today
por: Schwarb, Heike, et al.
Publicado: (2016)

Compliance and adherence to oral anticoagulation therapy in elderly patients with atrial fibrillation in the era of direct oral anticoagulants
por: Garkina, Svetlana V, et al.
Publicado: (2016)

Resistant and Resilient mutations in protection against familial Alzheimer’s disease: learning from nature
por: Sepulveda-Falla, Diego
Publicado: (2023)

Prophylactic Anticoagulation in Nephrotic Syndrome
por: Gerstein, Jonathon, et al.
Publicado: (2023)

The new K(V)3.4 inhibitor BDS-I[1–8] as a potential pharmacological opportunity in Alzheimer’s disease therapy
por: Piccialli, Ilaria, et al.
Publicado: (2020)

The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives
por: Walgrave, Hannah, et al.
Publicado: (2021)

Biomarker-guided drug therapy: personalized medicine for treating Alzheimer’s disease
por: Syal, Charvi, et al.
Publicado: (2021)

How useful are biomarkers for the diagnosis of Alzheimer’s disease and especially for its therapy?
por: Valenza, Marta, et al.
Publicado: (2022)

Anti-amyloid therapies for Alzheimer disease: finally, good news for patients
por: Ramanan, Vijay K., et al.
Publicado: (2023)

The brain compensatory mechanisms and Alzheimer's disease progression: a new protective strategy
por: Bobkova, Natalia, et al.
Publicado: (2015)

Microglial metabolic reconfiguration provides a new strategy for the treatment of Alzheimer’s disease
por: Leng, Lige, et al.
Publicado: (2023)

Factors associated with prescription of oral anticoagulants in the era of direct oral anticoagulants
por: Kataoka, Naoya, et al.
Publicado: (2023)

Is it necessary to alter anticoagulation therapy for tooth extraction in patients taking direct oral anticoagulants?
por: Caliskan, Mehmet, et al.
Publicado: (2017)

The efficacy and safety of out-hospital anticoagulation therapy with direct oral anticoagulant for COVID-19
por: Geng, Yu, et al.
Publicado: (2023)

Reversal of direct oral anticoagulants
por: Almegren, Mosaad
Publicado: (2017)

Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants
por: Favaloro, Emmanuel J., et al.
Publicado: (2022)

Galantamine protects against beta amyloid peptide-induced DNA damage in a model for Alzheimer's disease
por: Castillo, Willian O., et al.
Publicado: (2017)

How mind-body therapies might reduce pathological features of Alzheimer’s disease
por: Hüttenrauch, Melanie, et al.
Publicado: (2022)

Preventative medicine and Alzheimer’s disease: is Alzheimer’s disease risk reduction achievable?
por: Sinyor, Benjamin, et al.
Publicado: (2021)

Effectiveness and safety of self-managed oral anticoagulant therapy compared with direct oral anticoagulants in patients with atrial fibrillation
por: Grove, Erik Lerkevang, et al.
Publicado: (2018)

Direct-Acting Oral Anticoagulants as Prophylaxis Against Thromboembolism in the Nephrotic Syndrome
por: Sexton, Donal J., et al.
Publicado: (2018)

Licensed Anti-Microbial Drugs Logical for Clinical Trials against Pathogens Currently Suspected in Alzheimer’s Disease
por: Norins, Leslie C.
Publicado: (2021)

Implications of direct oral anticoagulation and antiplatelet therapy in intensive care
por: Willcox, Abbey, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mnd8eripai8g4v8q0gebgtg9qv